Is a complete NRXP research report available?

No complete published report is available for NRx Pharmaceuticals, Inc. (NRXP) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

NRx Pharmaceuticals, Inc. (NRXP)

NASDAQ: NRXP · USD

$3.75

-0.36 (-8.8%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-27 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first NRXP analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	157.2M
Revenue (ttm)	2.3M
Net income (ttm)	-24.5M
EPS (ttm)	-$0.97
Shares out	41.9M
Volume	791,603
Beta	2.19
Price target	$42.0	+1020.0%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 2.3M
Net income (ttm): -24.5M
EPS (ttm): -$0.97
Market cap: 157.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All NRXP indicators

Market & fundamental data

Available fields

192

Groups with data

Currency

USD

Showing 192 of 192 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001719406
Company name	NRx Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	629444209
Employees	29
Enterprise value	$151.4M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US6294442099
Last refreshed	2026-07-27
Market cap	$157.2M
Market cap category	Micro-Cap
Price	$3.75
Price currency	USD
Rev Per Employee	79,068.97x
Sector	Healthcare
Sector PE	44.88
Sector PE Fwd	23.79
Sic	2834
Symbol	NRXP
Website	https://www.nrxpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-15.61%
EV Sales Forward	4.06x
EV/Sales	66.02x
FCF yield	-9.5%
P/S ratio	68.54x
PS Forward	4.22x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	50.46%
Gross Profit	$1.2M
Net Income	$-24.5M
Net Income Growth Quarters	2%
Net Income Growth Years	0%
Pretax Margin	-1,070.21%
Profit Per Employee	$-846,207
ROA	-110.2
Roa5y	-175.2
ROCE	129

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	23.78%
Cagr3y	-3.06%
Cagr5y	-56.75%
EPS Growth Quarters	2
EPS Growth Years	4
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.24
Assets	$11.9M
Cash	$6.7M
Current Assets	$7.4M
Current Liabilities	$25.2M
Debt	$934,000
Equity	$-13.8M
Interest Coverage	-18.94
Liabilities	$25.7M
Long Term Assets	$4.5M
Long Term Liabilities	$543,000
Net Cash	$5.8M
Net Cash By Market Cap	$3.68
Tangible Book Value	$-16.5M
Tangible Book Value Per Share	$-0.49
WACC	16.65

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.29
Net Working Capital	$-24.1M
Quick ratio	0.27
Working Capital	$-17.8M
Working Capital Turnover	$-0.11

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-102.5%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	23.76%
200-day SMA	2.78
3Y total return	-8.89%
50-day SMA	3.93
50-day SMA vs 200-day SMA	50over200
5Y total return	-98.49%
All Time High	769.9
All Time High Change	-99.51%
All Time High Date	2020-12-22
All Time Low	1.1
All Time Low Change	240.91%
All Time Low Date	2024-10-16
ATR	0.34
Beta	2.19
Beta1y	2.19
Beta2y	0.81
Ch YTD	38.38
High	4.18
High52	5.06
High52 Date	2026-06-02
High52ch	-25.82%
Low	3.75
Low52	1.62
Low52 Date	2026-03-09
Low52ch	131.48%
Ma50ch	-4.6%
Premarket Change Percent	1.46
Premarket Price	$4.17
Premarket Volume	3,124
Price vs 200-day SMA	34.7%
RSI	42.82
RSI Monthly	44.5
RSI Weekly	59.07
Sharpe ratio	0.62x
Sortino ratio	1.11
Total Return	-102.5%
Tr YTD	38.38
Tr1m	-0.27%
Tr1w	-12.18%
Tr3m	32.04%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	2
Analyst Price Target Top	$35
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.12
Earnings Revenue Estimate	1,543,736x
Operating Income	$-17.2M
Operating margin	-749.6
Price target	$42
Price Target Change	$1,020
Price Target Change Top	$833

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	36,164,338%
Float Percent	86.29%
Net Borrowing	4,999,000
Shares Insiders	4.25%
Shares Institutions	11.97%
Shares Out	41,910,383
Shares Qo Q	11.62%
Shares Yo Y	102.5%
Short Float	14.92%
Short Ratio	3.85
Short Shares	12.88

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-15.9M
Average Volume	781,547.75x
Bv Per Share	-0.41
Ch1m	-0.27
Ch1w	-12.18
Ch1y	23.76
Ch3m	32.04
Ch3y	-8.89
Ch5y	-98.49
Ch6m	72.81
Change	-8.76%
Change From Open	-8.76
Close	4.11
Days Gap	0
Depreciation Amortization	132,000
Dollar Volume	2,968,511.3
Earnings Date	2026-08-17
Earnings Time	bmo
EBIT	$-17.1M
EBITDA	$-17M
EPS	$-0.97
F Score	2
FCF	$-14.9M
FCF EV Yield	-9.86x
FCF Per Share	$-0.36
Financing CF	19,115,000
Fiscal Year End	December
Founded	2,015
Goodwill	1,793,000
Investing CF	-3,023,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-15
Last Report Date	2026-03-31
Last Split Date	2024-04-02
Last Split Type	Reverse
Last10k Filing Date	2026-03-23
Ma150	2.82
Ma150ch	32.98%
Ma20	4.12
Ma20ch	-8.87%
Net CF	1,165,000
Next Earnings Date	2026-08-17
Open	4.11
Optionable	Yes
Position In Range	0
Post Close	3.75
Postmarket Change Percent	0.27
Postmarket Price	$3.76
Ppne	1,195,000
Pre Close	4.11
Price Date	2026-07-24
Relative Volume	1.01x
Revenue	2,293,000x
SBC By Revenue	42.22x
Share Based Comp	968,000
Tr6m	72.81%
Us State	Delaware
Volume	791,603
Z Score	-41.25

NRx Pharmaceuticals, Inc. (NRXP)

Coverage state: Market snapshot only — no published research

Generate the first NRXP analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · NRXP

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NRXP indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on NRXP

Frequently asked questions